Trial · NCT01370460
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
NCT01370460, Phase 2, Completed, Henry Ford Health System; results first posted 2013-07-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty. Trials, record NCT01370460. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01370460
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
- NCT number
- NCT01370460
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 101 participants, actual
- Lead sponsor
- Henry Ford Health System
- Conditions
- Acute Blood Loss Anemia, Osteoarthritis, Knee
- Interventions
- Tranexamic Acid, Placebo
- First posted
- 2011-06-10
- Last updated
- 2023-04-25
- Results first posted
- 2013-07-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood Loss | participants will be followed for the duration of hospital stay, an expected average of 3 days | Preoperative and lowest postoperative hemoglobin. Blood loss was calculated taking change in hemoglobin as described (units g/dL) and converting to blood loss (mL) according to the formulas included in the papers cited in this entry (Good 2003 Br J Anesthesia; Nadler 1962 Surgery, http://www.ncbi.nlm.nih.gov/pubmed/21936146). |
| Secondary | Postoperative Transfusion Rate | participants will be followed for the duration of hospital stay, an expected average of 3 days | Number of patients with symptomatic (tachycardia, hypotension, presyncope) anemia of \< 8.0g/dL hemoglobin, or any hemoglobin \<7.0 g/dL, precipitated transfusion. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Blood Loss | participants will be followed for the duration of hospital stay, an expected average of 3 days | mL | MEAN | |
| SECONDARY | Postoperative Transfusion Rate | participants will be followed for the duration of hospital stay, an expected average of 3 days | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Blood Loss | Placebo | 1293.1 | Standard Deviation 532.7 | mL | |
| Blood Loss | Tranexamic Acid | 940.2 | Standard Deviation 327.1 | mL | |
| Postoperative Transfusion Rate | Tranexamic Acid | 0 | participants | ||
| Postoperative Transfusion Rate | Placebo | 4 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tranexamic Acid | 50 | |
| Overall Study | STARTED | Placebo | 51 | |
| Overall Study | COMPLETED | Tranexamic Acid | 50 | |
| Overall Study | COMPLETED | Placebo | 51 | |
| Overall Study | NOT COMPLETED | Tranexamic Acid | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adverse Events Not Collected | ||
| Total, other adverse events | Adverse Events Not Collected | 0 | 0 |
| Total, serious adverse events | Adverse Events Not Collected | 0 | 0 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Tranexamic Acid vs Placebo: Postoperative Transfusion Rate |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01370460
GET https://conductscience.org/api/trials/v1/NCT01370460/registered